Katerina Kotlabova
Overview
Explore the profile of Katerina Kotlabova including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
820
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hromadnikova I, Kotlabova K, Krofta L
Front Med (Lausanne)
. 2024 Dec;
11:1469855.
PMID: 39691371
Background: Placenta previa is the abnormal implantation of the placenta into the lower segment of the uterus, is associated with adverse maternal and fetal outcomes such as placenta accreta spectrum...
2.
Hromadnikova I, Kotlabova K, Krofta L
Front Cell Dev Biol
. 2024 Sep;
12:1461547.
PMID: 39296937
Introduction: This study aimed to establish efficient, cost-effective, and early predictive models for adverse pregnancy outcomes based on the combinations of a minimum number of miRNA biomarkers, whose altered expression...
3.
Hromadnikova I, Kotlabova K, Krofta L
Mol Cell Probes
. 2023 Nov;
72:101941.
PMID: 37951512
We established efficient first trimester prediction models for small-for-gestational age (SGA) and fetal growth restriction (FGR) without the presence of preeclampsia (PE) regardless of the gestational age of the onset...
4.
Hromadnikova I, Kotlabova K, Krofta L
Int J Mol Sci
. 2023 Jun;
24(12).
PMID: 37373283
We evaluated the potential of cardiovascular-disease-associated microRNAs to predict in the early stages of gestation (from 10 to 13 gestational weeks) the occurrence of a miscarriage or stillbirth. The gene...
5.
Hromadnikova I, Kotlabova K, Krofta L
Int J Mol Sci
. 2023 Mar;
24(6).
PMID: 36982251
We evaluated the potential of cardiovascular-disease-associated microRNAs for early prediction of HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome. Gene expression profiling of 29 microRNAs was performed on whole...
6.
Hromadnikova I, Kotlabova K, Krofta L
Biomedicines
. 2022 Oct;
10(10).
PMID: 36289853
The goal of the study was to establish an efficient first-trimester predictive model for any type of preterm birth before 37 gestational weeks (spontaneous preterm birth (PTB) or preterm prelabor...
7.
Hromadnikova I, Kotlabova K, Krofta L
Int J Mol Sci
. 2022 Sep;
23(18).
PMID: 36142536
We assessed the diagnostic potential of cardiovascular disease-associated microRNAs for the early prediction of gestational diabetes mellitus (GDM) in singleton pregnancies of Caucasian descent in the absence of other pregnancy-related...
8.
Hromadnikova I, Kotlabova K, Krofta L
Int J Mol Sci
. 2022 Apr;
23(7).
PMID: 35409311
The aim of the study was to determine if aberrant expression profile of cardiovascular disease associated microRNAs would be able to predict within 10 to 13 weeks of gestation preterm...
9.
Hromadnikova I, Kotlabova K, Krofta L
Biomedicines
. 2022 Mar;
10(3).
PMID: 35327520
The goal of the study was to determine the early diagnostical potential of cardiovascular disease-associated microRNAs for prediction of small-for-gestational-age (SGA) and fetal growth restriction (FGR) without preeclampsia (PE). The...
10.
Hromadnikova I, Kotlabova K, Krofta L
Biomedicines
. 2022 Feb;
10(2).
PMID: 35203467
The aim of the study was to assess if cardiovascular disease-associated microRNAs would be able to predict during the early stages of gestation (within 10 to 13 weeks) subsequent onset...